Status:

COMPLETED

Efficacy and Safety of ALGRX 4975 in the Treatment of Postoperative Pain After Gall Bladder Removal

Lead Sponsor:

AlgoRx Pharmaceuticals

Conditions:

Postoperative Pain

Eligibility:

All Genders

20-65 years

Phase:

PHASE2

Brief Summary

Postoperative pain after gall bladder removal can be significant, mobility limiting and extend hospital stay. ALGRX 4975 is an ultra-pure form of capsaicin, which is a pain medicine that has the poten...

Detailed Description

Postoperative pain after open cholecystectomy can be significant and mobility limiting, causing increased risk of deep venous thrombosis, pulmonary complications, and extended hospital stay. With incr...

Eligibility Criteria

Inclusion

  • Subjects undergoing open cholecystectomy with the subcostal approach for cholelithiasis/cholecystitis
  • American Society of Anesthesiologists (ASA) Class I or II

Exclusion

  • Active pancreatitis, any obstruction of the biliary tree, or hyperbilirubinemia (total bilirubin \> 2.5 mg/dL)
  • Previous abdominal surgical procedure with the exception of inguinal hernia repair or appendectomy by the lateral approach or cesarean section or hysterectomy if the surgery was performed more than 1 year prior to study participation and the subject experienced no postoperative complications
  • Diabetes mellitus with HbA1C \> 9.5 or a history of prolonged uncontrolled diabetes mellitus
  • Systolic blood pressure greater than 150 mmHg or diastolic greater than 95 mmHg

Key Trial Info

Start Date :

July 1 2005

Trial Type :

INTERVENTIONAL

End Date :

December 1 2005

Estimated Enrollment :

40 Patients enrolled

Trial Details

Trial ID

NCT00133133

Start Date

July 1 2005

End Date

December 1 2005

Last Update

December 20 2006

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Emergency Center, Clinical Center of Serbia

Belgrade, Serbia and Montenegro, 11000